The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors through allosteric signaling.

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...